Literature DB >> 15124762

Cytokine mRNA expression in patients with multiple sclerosis and fatigue.

Peter Flachenecker1, Irene Bihler, F Weber, M Gottschalk, Klaus V Toyka, Peter Rieckmann.   

Abstract

BACKGROUND: Fatigue is one of the most common disabling symptoms in patients with multiple sclerosis (MS), but the putative role of proinflammatory cytokines remains to be elucidated.
METHODS: Thirty-seven patients (27 women, 10 men) with relapsing remitting (n = 29) and secondary progressive (n = 8) MS, aged 41.0 +/- 10.2 years, were studied. Fatigue was assessed by Krupp's Fatigue Severity Scale (FSS). Cytokine mRNA expression for interferon (IFN)-gamma tumor necrosis factor (TNF)-alpha and interleukin (IL)-10 were measured by real time RT PCR. Autonomic function was evaluated by standard tests for parasympathetic and sympathetic function, as well as by serum levels of norepinephrine and epinephrine.
RESULTS: Median levels of TNF-alpha mRNA expression were significantly higher in MS patients with (FSS > or = 4.0 and > or = 5.0, n = 26 and n = 14, respectively) than in those without fatigue (FSS < 4.0, n = 11). No differences were seen for IFN-gamma and IL-10 mRNA expression. Cytokine levels were not correlated to autonomic tests or to serum catecholamine levels.
CONCLUSIONS: These results suggest that TNF-alpha, as a principal proinflammatory mediator, is associated with MS-related fatigue. This is in support of a pathogenic role of the MS-related inflammatory process in the development of fatigue.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15124762     DOI: 10.1191/1352458504ms991oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  53 in total

Review 1.  Biomarkers for chronic fatigue.

Authors:  Nancy G Klimas; Gordon Broderick; Mary Ann Fletcher
Journal:  Brain Behav Immun       Date:  2012-06-23       Impact factor: 7.217

Review 2.  A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-06-21       Impact factor: 3.584

Review 3.  Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment.

Authors:  Tiffany J Braley; Ronald D Chervin
Journal:  Sleep       Date:  2010-08       Impact factor: 5.849

4.  Multiple sclerosis related fatigue.

Authors:  G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 5.  Neuropsychological/-psychiatric deficits in immune-mediated neuropathies.

Authors:  Andrew Chan; Ralf Gold
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

6.  Effect of aerobic interval training on serum IL-10, TNFα, and adipokines levels in women with multiple sclerosis: possible relations with fatigue and quality of life.

Authors:  Motahare Mokhtarzade; Rouholah Ranjbar; Nastaran Majdinasab; Darpan Patel; Mehdieh Molanouri Shamsi
Journal:  Endocrine       Date:  2017-06-14       Impact factor: 3.633

7.  Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?

Authors:  C Heesen; L Nawrath; C Reich; N Bauer; K-H Schulz; S M Gold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 8.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

9.  Fatigue: an important feature of late-onset Pompe disease.

Authors:  Marloes L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

10.  The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis.

Authors:  Nicole M Stroud; Clare L Minahan
Journal:  Health Qual Life Outcomes       Date:  2009-07-20       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.